Intellia Therapeutics Gets FDA Green Light to Initiate U.S. CRISPR Trial for Hereditary Angioedema
Intellia Therapeutics recently announced that the FDA has cleared an Investigational New Drug application for NTLA-2002, a single-dose in vivo CRISPR therapeutic candidate designed to cure hereditary angioedema. This allows the company to include the United States in the global Phase 2 portion of Intellia's ongoing Phase 1/2 trial of NTLA-2002.